# Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

> **NCT06600581** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Immunis, Inc.** · enrollment: 55 (estimated)

## Conditions studied

- Muscle Performance
- Sarcopenic Obesity

## Interventions

- **BIOLOGICAL:** IMM01-STEM
- **OTHER:** Placebo
- **BIOLOGICAL:** IMM01-STEM alternating with placebo (saline)

## Key facts

- **NCT ID:** NCT06600581
- **Lead sponsor:** Immunis, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-19
- **Primary completion:** 2026-07-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06600581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06600581, "Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06600581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*